Vaxcyte Total Current Liabilities from 2010 to 2025
| PCVX Stock | USD 70.77 2.21 3.22% |
Total Current Liabilities | First Reported 2019-12-31 | Previous Quarter 123.8 M | Current Value 140.2 M | Quarterly Volatility 38.1 M |
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 115.5 M, Interest Expense of 0.0 or Selling General Administrative of 97.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
Vaxcyte | Total Current Liabilities |
Latest Vaxcyte's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Vaxcyte over the last few years. Total Current Liabilities is an item on Vaxcyte balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Vaxcyte are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Vaxcyte's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Vaxcyte Total Current Liabilities Regression Statistics
| Arithmetic Mean | 37,542,375 | |
| Geometric Mean | 13,570,785 | |
| Coefficient Of Variation | 145.67 | |
| Mean Deviation | 41,547,641 | |
| Median | 6,713,000 | |
| Standard Deviation | 54,688,648 | |
| Sample Variance | 2990.8T | |
| Range | 142.9M | |
| R-Value | 0.79 | |
| Mean Square Error | 1188.2T | |
| R-Squared | 0.63 | |
| Significance | 0.0002 | |
| Slope | 9,111,724 | |
| Total Sum of Squares | 44862.7T |
Vaxcyte Total Current Liabilities History
About Vaxcyte Financial Statements
Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 140.2 M | 147.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.